Anbio Biotechnology Class A Ordinary Shares

NASDAQ:NNNN

Medical - Instruments & Supplies

Healthcare
$3.60 +2.30%

+$0.37 today

Market cap
$158.01M
Beta
4.34
P/E (TTM)
99.1
EPS (TTM)
$0.16
52W Low $10.50High $55.65

Volume 0.09M

Average 0.03M

NNNN Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Anbio Biotechnology Class A Ordinary SharesNASDAQ: NNNN

Gross Margin · Q4 FY2025 · quarter ended Dec 2025

Gross margin narrows to 81.5%

Gross margin was 81.5% in Q4 FY2025, down 3.1 pp from a year earlier. Over 3 fiscal years it widened by 33.9 pp.

Context

  • Gross margin widened in 2 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterDec 2025
81.5%— QoQ
Last fiscal yearDec 2025
87.2%+15.3 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-3.1 pp——
1 year+15.3 pp——
3 years+33.9 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
87.2%
Year-over-year change
+15.3pp

Gross Margin vs competitors

How NNNN compares with its peers on the latest reported figures

  • NNNN's FY2025 gross margin of 87.2% is the 4th highest of the 10 companies compared; the peer median is 53.7%.
  • Its year-over-year change of +15.3 pp is the highest of 9, against a peer median of +0.1 pp.
  • Over three fiscal years its change of +33.9 pp compares with a peer median of -5.2 pp.
NNNN Competitors Peer median
Gross Margin for NNNN and competitors
Company Period LTM level YoY 3-year change
GOSSGossamer Bio, Inc.LTM Mar 202699.6% -0.4 pp—
RIGLRigel Pharmaceuticals, Inc.LTM Mar 202693.4% +3.7 pp-5.2 pp
KALVKalVista Pharmaceuticals, Inc.LTM Dec 202592.0% ——
NNNNAnbio Biotechnology Class A Ordinary SharesFY202587.2% +15.3 pp+33.9 pp
CLPTClearPoint Neuro, Inc.LTM Mar 202661.8% +0.6 pp-4.5 pp
CYHCommunity Health Systems, Inc.LTM Mar 202653.7% +11.9 pp-31.5 pp
ANGOAngioDynamics, Inc.LTM Feb 202653.5% -0.9 pp+1.5 pp
AVNSAvanos Medical, Inc.LTM Mar 202648.6% -6.2 pp-7.9 pp
TALKTalkspace, Inc.LTM Mar 202642.2% -2.8 pp-7.5 pp
SNDLSNDL Inc.LTM Mar 202627.2% +0.6 pp+7.6 pp
CMPSCOMPASS Pathways plcFY2025— ——
Peer median (excluding NNNN) 53.7%+0.1 pp-5.2 pp

Competitors are the stored peer set for NNNN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue4.43M23.54M6.71M8.19M9.76M
Cost of Revenue1.89M10.98M3.35M2.3M1.25M
Gross Profit2.54M12.56M3.36M5.89M8.51M
Gross Margin57.4%53.4%50.1%71.9%87.2%
Research & Development0200K134.7K454.23K227.19K
Selling, General & Admin86.1K2.17M1.27M3.44M1.78M
Operating Expenses86.1K2.37M1.4M3.89M2M
Depreciation & Amortization06.25K13.04K00
EBITDA2.54M10.03M2.27M2.57M6.51M
EBITDA Margin57.3%42.6%33.8%31.4%66.7%
Operating Income2.46M10.2M1.96M2M6.51M
Operating Margin55.5%43.3%29.2%24.4%66.7%
Interest Income042.25K165.34K337.51K160.28K
Interest Expense08K000
Other Income / Expenses79.94K(184.41K)292.78K377.48K717.46K
Income Before Tax2.54M10.01M2.25M2.37M7.23M
Pre-Tax Margin57.3%42.5%33.6%29.0%74.1%
Income Tax Expense00000
Net Income2.54M10.01M2.25M2.37M7.23M
Net Margin57.3%42.5%33.6%29.0%74.1%
EPS (Basic)0.030.070.020.060.16
EPS (Diluted)0.030.070.010.060.16
Weighted Avg Shares100M143.89M143.89M42.29M43.89M
Weighted Avg Shares (Diluted)100M143.89M187.78M42.29M43.89M

Anbio Biotechnology Class A Ordinary Shares

NASDAQ:NNNN

Intrinsic Alpha fair value

Locked

Current Price

$3.60

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.